Pfizer: FDA votes in favour of RSV vaccine

(CercleFinance.com) - Pfizer today announced that the Vaccine and Related Biologics Advisory Committee (VRBPAC) of the US FDA has voted in favor of the efficacy and safety of its non-adjuvanted bivalent respiratory syncytial virus (RSV) vaccine candidate.


The candidate vaccine is currently under review by the FDA for the prevention of medically monitored lower respiratory tract disease (MRTLD) and severe lower respiratory tract disease caused by RSV in infants from birth to six months of age through active immunisation of pregnant women.

If approved, Pfizer said that its vaccine could be the first maternal vaccine to protect infants through the first six months of life against this potentially serious infection.


Copyright (c) 2023 CercleFinance.com. All rights reserved.